Federal Research Centre of Nutrition, Biotechnology and Food Safety, Department of Gastroenterology & Hepatology, 109240 Moscow, Russia.
I. M. Sechenov First Moscow State Medical University, 119435 Moscow, Russia.
Viruses. 2022 Apr 11;14(4):790. doi: 10.3390/v14040790.
Hepatitis C virus (HCV) is highly prevalent in Russia, representing the largest pool of hepatitis C patients in Europe. Effective treatment regimens with direct-acting antivirals can achieve HCV cure in all patients; therefore, in 2016 the World Health Organization proposed eliminating hepatitis C as a public health threat by 2030. However, only a small number of countries are on track to meet the WHO's hepatitis C elimination targets by 2030 due to many barriers in healthcare systems. This review focuses on a discussion about the epidemiology of HCV in Russia, the economic burden of HCV-related diseases, and treatment access with particular reference to the barriers for the elimination of HCV.
丙型肝炎病毒（HCV）在俄罗斯广泛流行，是欧洲最大的丙型肝炎患者群体。直接作用抗病毒药物的有效治疗方案可以使所有患者实现 HCV 治愈；因此，世界卫生组织于 2016 年提议到 2030 年消除丙型肝炎对公共卫生的威胁。然而，由于医疗体系中存在许多障碍，只有少数几个国家有望实现 2030 年消除丙型肝炎的世卫组织目标。本综述重点讨论了俄罗斯 HCV 的流行病学、HCV 相关疾病的经济负担以及特定治疗途径，特别提到了消除 HCV 的障碍。
